Revumenib
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 87 publications
The All-Oral Combination of Revumenib, Decitabine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (SAVE).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 11, 2026
Emerging drug profile: menin inhibitors in NPM1-mutated and KM2A-rearranged acute myeloid leukemia.
Journal: Leukemia & lymphoma
Published: May 27, 2026
Ziftomenib (Komzifti) for acute myeloid leukemia.
Journal: The Medical letter on drugs and therapeutics
Published: March 07, 2026
Successful Management of Lineage Switch Infant Leukemia With Revumenib and Hematopoietic Cell Transplantation.
Journal: Pediatric blood & cancer
Published: March 04, 2026
Concurrent therapy-related acute myeloid leukemia and lymph node tuberculosis following treatment for lung squamous cell carcinoma: a case report and literature review.
Journal: Frontiers in oncology
Published: February 28, 2026
Differentiation therapy in acute myeloid leukaemia: molecular basis, clinical progress, and future perspectives.
Journal: Frontiers in medicine
Published: February 26, 2026
Targeted Therapy in Acute Myeloid Leukemia: Current Approaches and Novel Directions.
Journal: Journal of personalized medicine
Published: February 16, 2026
Targeting the Menin-KMT2A Axis in Acute Leukemia: From Epigenetic Dependency to Clinical Translation.
Journal: European journal of haematology
Published: January 29, 2026
Menin Inhibition in Acute Myeloid MLL Rearranged Leukemias: A New Target for Precision Care.
Journal: Cancers
Published: January 20, 2026
Last Updated: 06/30/2026